Sharpe v. Roth, 502 U.S. 856 (1991). · Go Syfert
Search
Sharpe v. Roth, 502 U.S. 856 (1991). Cases Citing This Book View Copy Cite
87 citation events (6 in the last 25 years) across 24 distinct courts.
Strongest positive: Minco, Inc., Plaintiff/cross-Appellant v. Combustion Engineering, Inc. (cafc, 1996-11-18) · Strongest negative: Pall Corp. v. Micron Separations, Inc. (mad, 1992-04-24)
Treatment trajectory · 1992 → 2026 · click a year to view as-of
1992 2009 2026
Top citers, strongest first. 20 distinct citers. How cited ↗
discussed Cited "but see" Pall Corp. v. Micron Separations, Inc.
D. Mass. · 1992 · signal: but see · confidence high
Gore & Assocs., 842 F.2d at 1280; Hybritech, Inc., 802 F.2d at 1385 ; but see Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd., 927 F.2d 1200, 1217-18 (Fed.Cir.), cert. denied sub nom., Genetics Institute v. Amgen, Inc., — U.S. -, 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991).
discussed Cited "see" Minco, Inc., Plaintiff/cross-Appellant v. Combustion Engineering, Inc.
Fed. Cir. · 1996 · signal: accord · confidence high
Spectra-Physics, 827 F.2d at 1536 ; accord Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 1209 , 18 USPQ2d 1016, 1024 (Fed.Cir.), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991).
cited Cited "see" Johns Hopkins University v. CellPro
D. Del. · 1996 · signal: see · confidence high
See Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 1212-1214 (Fed.Cir.), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991).
discussed Cited "see" In Re Thomas F. Deuel, Yue-Sheng Li, Ned R. Siegel and Peter G. Milner
Fed. Cir. · 1995 · signal: see · confidence high
See generally Amgen Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 1212-14 , 18 USPQ2d 1016, 1026-28 (Fed.Cir.) (generic DNA sequence claims held invalid under 35 U.S.C. § 112 , first paragraph), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991); In re Fisher, 427 F.2d 833, 839 , 166 USPQ 18 , 24 (CCPA 1970) (Section 112 “requires that the scope of the claims must bear a reasonable correlation to the scope of en-ablement provided by the specification to persons of ordinary skill in the art.”).
discussed Cited "see" In Re Thomas P.H. Warmerdam and Bernard J.H. Verwer
Fed. Cir. · 1994 · signal: see · confidence high
See Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200, 1217 , 18 USPQ2d 1016, 1030 (Fed.Cir.), cert. denied sub nom., Genetics Inst., Inc. v. Amgen, Inc., — U.S. -, 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991) (citing Shatterproof Glass Corp. v. Libbey-Owens Ford Co., 768 F.2d 613, 624 , 225 USPQ 634, 641 (Fed.Cir.1985)).
cited Cited "see" Amgen, Inc. v. Elanex Pharmaceuticals, Inc.
W.D. Wash. · 1994 · signal: see · confidence high
See Amgen Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 (Fed.Cir.), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991).
cited Cited "see" In Re Graeme I. Bell, Leslie B. Rall and James P. Merryweather
Fed. Cir. · 1993 · signal: see · confidence high
See Amgen Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 , 1207-08 n. 4, 18 USPQ2d 1016, 1022 n. 4 (Fed.Cir.), ce rt. denied, — U.S.-, 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991). 6 .
discussed Cited "see" Zumbro, Inc. v. Merck & Co.
N.D. Ill. · 1993 · signal: see · confidence high
See Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd., 927 F.2d 1200, 1211 (Fed.Cir.) (lack of sample of biological cells does not constitute failure to comply with best mode requirement if cells can be prepared without undue experimentation from known materials, based on patent description), cert. denied, — U.S. —, 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991).
discussed Cited "see" Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd.
D. Mass. · 1992 · signal: see · confidence high
See Amgen, Inc. v. Chugai Pharmaceutical Co., 706 F.Supp. 94 (D.Mass.1989) (“Amgen I”), aff'd in part and rev’d in part, Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 (Fed.Cir.1991) (“Amgen II”), cert. denied, — U.S. -, 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991).
cited Cited "see" Conopco, Inc. v. May Dept. Stores Co.
E.D. Mo. · 1992 · signal: see · confidence high
See Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 1217-18 (Fed.Cir.1991), cert. denied, ___ U.S. ___, 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991).
discussed Cited "see, e.g." Benedict v. General Motors Corp.
N.D. Fla. · 2002 · signal: see, e.g. · confidence low
See, e.g., Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 , 18 USPQ2d 1016 (Fed.Cir.), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991); New Idea Farm Equipment Corp. v. Sperry Corp., 916 F.2d 1561 , 16 USPQ2d 1424 (Fed.Cir.1990) ....
cited Cited "see, e.g." Mycogen Plant Science, Inc. v. Monsanto Co.
D. Del. · 1999 · signal: see, e.g. · confidence low
See, e.g., Amgen Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 , 1207-08 n. 4, (Fed.Cir.), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991). 3 .
discussed Cited "see, e.g." Sea Robin Pipeline Co. v. Red Sea Group, Ltd.
W.D. La. · 1996 · signal: see also · confidence low
See, also, Northern Natural Gas Co. v. F.E.R.C., 929 F.2d 1261 , 1265 (8th Cir.1991) (Brown, J., sitting by designation), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991); Northwest Pipeline Corp. v. F.E.R.C., 905 F.2d 1403 , 1404 (10th Cir.1990).
discussed Cited "see, e.g." Checkpoint Systems, Inc. v. United States International Trade Commission
Fed. Cir. · 1995 · signal: see, e.g. · confidence low
See, e.g., Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 , 18 USPQ2d 1016 (Fed.Cir.), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991); New Idea Farm Equipment Corp. v. Sperry Corp., 916 F.2d 1561 , 16 USPQ2d 1424 (Fed.Cir.1990).
discussed Cited "see, e.g." Checkpoint Systems, Inc. v. The United States International Trade Commission
Fed. Cir. · 1995 · signal: see, e.g. · confidence low
See, e.g., Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 , 18 USPQ2d 1016 (Fed.Cir.), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991); New Idea Farm Equipment Corp. v. Sperry Corp., 916 F.2d 1561 , 16 USPQ2d 1424 (Fed.Cir.1990).
discussed Cited "see, e.g." Continental Trend Resources, Inc. v. OXY Usa Inc.
10th Cir. · 1995 · signal: see also · confidence low
Colorado Interstate Gas Co. v. FERC, 890 F.2d 1121 , 1123 (10th Cir.1989) (citations omitted); see also Northern Natural Gas Co., (Div. of Enron Corp.) v. FERC, 929 F.2d 1261, 1263-64 (8th Cir.), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991) (open access policy was means by which FERC sought to increase competition in the market for natural gas).
discussed Cited "see, e.g." Continental Trend Resources, Inc. Harold G. Hamm, Trustee of the Harold G. Hamm Revocable Inter Vivos Trust Gary H. Wright Cindy Wright Jeffrey B. Hume Farrar Oil Company v. Oxy USA Inc., and Williams Natural Gas Company, Continental Trend Resources, Inc. Harold G. Hamm, Trustee of the Harold G. Hamm Revocable Inter Vivos Trust Gary H. Wright Cindy Wright Jeffrey B. Hume Farrar Oil Company v. Oxy USA Inc. And Williams Natural Gas Company
10th Cir. · 1995 · signal: see also · confidence low
The purpose ... is to increase downstream competition in natural gas sales by ensuring that sellers who do not transport their own gas have access to transportation facilities. 8 Colorado Interstate Gas Co. v. FERC, 890 F.2d 1121 , 1123 (10th Cir.1989) (citations omitted); see also Northern Natural Gas Co., (Div. of Enron Corp.) v. FERC, 929 F.2d 1261, 1263-64 (8th Cir.), cert. denied, 502 U.S. 856 , 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991) (open access policy was means by which FERC sought to increase competition in the market for natural gas).
discussed Cited "see, e.g." Genentech, Inc. v. The Wellcome Foundation Limited
Fed. Cir. · 1994 · signal: see also · confidence low
See In re Fisher, 427 F.2d 833, 838-40 , 166 USPQ 18 , 23-24 (CCPA 1970); see also Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200, 1212-14 , 18 USPQ2d 1016, 1026-28 (Fed.Cir.), cert. denied sub nom., Genetics Inst., Inc. v. Amgen, Inc., --- U.S. ----, 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991). 51 Plaintiffs argue that a protein (25E10) discussed in the specification provides a basis for interpreting the phrase "human tissue plasminogen activator" appearing in the claims broadly, on the theory that claims are to be interpreted in light of the disclosure of examples in the specificatio…
discussed Cited "see, e.g." Genentech, Inc. v. Wellcome Foundation Ltd.
Fed. Cir. · 1994 · signal: see also · confidence low
See In re Fisher, 427 F.2d 833, 838-40 , 166 USPQ 18 , 23-24 (CCPA 1970); see also Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200, 1212-14 , 18 USPQ2d 1016, 1026-28 (Fed.Cir.), cert. denied sub nom., Genetics Inst., Inc. v. Amgen, Inc., — U.S. -, 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991).
cited Cited "see, e.g." Brown v. Regents of the University of California
N.D. Cal. · 1994 · signal: see, e.g. · confidence low
See, e.g., Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200 (Fed.Cir.1991), cert. denied, — U.S. -, 112 S.Ct. 169 , 116 L.Ed.2d 132 (1991).
Retrieving the full opinion text from the archive…
Sharpe
v.
Roth
No. 91-18.
Supreme Court of the United States.
Oct 7, 1991.
502 U.S. 856
Published

C. A. 3d Cir. Certiorari denied.